Perrigo Q2 2023 Earnings Call Transcript

Quartr
Provided by Quartr
August 8, 2023

Key Takeaways

  • Perrigo reported Q2 net sales up 6.4%, gross margin expansion of 220 bps, 18% operating income growth and 47% EPS growth, ending the quarter with CAD 555 M in cash and net leverage down to 5.1x EBITDA.
  • New President & CEO Patrick Lockwood Taylor outlined a framework for sustainable growth focused on refining where to play, defining how to win and optimizing a one-Perrigo operating model.
  • FDA approved Opill, the first OTC daily oral contraceptive in the U.S., with planned retailer shelf launch in early 2024 and investment in prelaunch activities despite no accretion expected in the first 12–24 months.
  • Infant formula business integration of the Gateway acquisition added CAD 44 M in Q2, but new FDA guidelines have constrained production, causing supply delays even as demand outstrips Perrigo’s current capacity.
  • Supply chain reinvention delivered a 40 bps gross margin uplift in the Americas via SKU prioritization and has rolled out Perrigo Work System tech on 35% of manufacturing lines to drive efficiency and cost savings.
AI Generated. May Contain Errors.
Earnings Conference Call
Perrigo Q2 2023
00:00 / 00:00

There are 7 speakers on the call.

Operator

Please note this event is being recorded. I would now like to turn the conference over to Bradley Joseph, Vice President, Investor Relations. Please go ahead.

Speaker 1

Good morning, and welcome to Perrigo's Q2 2023 earnings conference call. I hope you all had a chance to review our release issued this morning. A copy of the earnings release and presentation for today's discussion are available within the Investors section of the perrigo.com website. For the first time, I would like to introduce and welcome Perrigo's newly appointed President and CEO, Patrick Lockwood Taylor to the call. Patrick, on behalf of shareholders, we are thrilled to have you at Perrigo.

Speaker 1

Your consumer's self care experience and expertise will bring a fresh perspective Help inspire the organization to achieve even greater heights. Again, welcome. Also joining the call this morning is Perrigo's CFO, Eduardo Bizerro. I would like to remind everyone that during this call, participants will make certain forward looking statements. Please refer to the important information for shareholders and investors And safe harbor language regarding these statements in our press release issued earlier this morning.

Speaker 1

A few quick items before we start. 1st, Unless stated, all financial results discussed and presented are on a continuing operations basis. They do not include any contributions from the divested Rx business, Which was accounted for as discontinued operations prior to its sale. 2nd, organic growth excludes acquisitions, divestitures, Exited product lines and currency in both comparable periods. All comments related to constant currency remove the impact of currency translation versus the prior year By applying the exchange rates used in the comparable measurement in the prior year's financial statements.

Speaker 1

And third, Patrick's discussion will focus solely Our non GAAP results, except as otherwise expressly noted, see the appendix for additional details and for reconciliations of all Non GAAP Financial Measures is present. And with that, I'd like to turn the call over to Patrick.

Speaker 2

Thank you for the warm welcome, Brad, and Thank you everybody for joining us this morning. I'm nearly 40 days into my Perrigo tenure and I greatly appreciate the warm welcome I have received from my Perrigo colleagues. The pride and excitement for our business comes through in every interaction, and I'm very energized to join them in the next phase of Perrigo's growth. I I also want to recognize and thank Murray Kessler, our outgoing CEO, for his leadership in positioning Perrigo as a major player in global self care. I'd like to start the call today by sharing what excites me most about the opportunities at Perrigo I'd also provide thoughts on our framework for building long term sustainable growth.

Speaker 2

I've actually followed Perrigo for several years now I have always believed this is a truly unique business. It's well positioned in the right industry with numerous strengths and let me highlight a few of those. It has tremendous manufacturing scale in the U. S. With the ability to produce over 50,000,000,000 doses every year This manufacturing capability translates into nearly 1600 doses produced every second of every day.

Speaker 2

That's incredible consumer reach. As a global company, Perrigo has strong customer relationships with the top U. S. Retailers in addition to strong pharmacy relationships across Europe With over 100,000 direct pharmacist partners, Perrigo embodies a solid focus on cash and cash flow mindset, which Including prioritization, simplification, standardization and pricing. Finally, Perrigo has a strong innovation engine ability to fast follow across nearly every major OTC category.

Speaker 2

In fact, Perrigo has more approved OTC Anders than any other company. Our fast follow ability is exemplified by the launches of store brand equivalent to Voltaren Pain Relief Gel and Advil Dual Action Tablets, Both of which were launched the day after the national brand exclusivity expired. This innovation and speed to market enables our retail partners to Truly differentiate their brands on the shelf. Another exciting example of our innovation is Opel, which I will discuss further in a few minutes. There's been a lot of work accomplished over the past 5 years to position Perrigo as a leading company in the consumer self care space, There is still an awful lot of work to do to consistently win and to fully capitalize on our assets and our opportunities.

Speaker 2

So a few thoughts on the building blocks that will drive sustainable growth. 1st is to continue to refine where we are going to play. Perrigo has made great progress defining where to play within branded self care. Yes, store brands are indeed branded self care, but this will continue to evolve. Within consumer self care, Perrigo participates in attractive segments that are set to benefit from favorable tailwinds, Aging world populations, a heightened focus on self care treatment and ever more cost burden shifting to consumers It's set to drive attractive category growth.

Speaker 2

Next is to define how we're going to win. It is early in my tenure, but I can tell you Perrigo has a lot of tools to differentiate from competition and to win with consumers, Including e commerce leadership and an extensive portfolio with deep category insights and world class manufacturing, innovation and scale. It is our job to better leverage these tools to win consistently with consumers in a differentiated and impactful way. Dan, understanding how we can further leverage our existing capabilities in addition to new capabilities that we might need This is on track to drive down cost to increase efficiencies and to better leverage our manufacturing scale. Going forward, we will look to accelerate additional capabilities, including brand building and more meaningful consumer driven innovation So that we might differentiate our products at shelf.

Speaker 2

Finally, to optimize the Perrigo operating model and to Performed better as one perigot. While there has already been a lot of progress here, for example, our supply chain reinvention program, We have more to do to harmonize our global operating model. We will sink to 1 operational drumbeat with common systems, structures and KPIs That we can deliver our products to consumers in the most efficient value creating way. Now, A brief update on our accretive initiatives. First is the progress we continue to make on our supply chain reinvention program.

Speaker 2

Perrigo work system is being rolled out across our manufacturing footprint. This foundational technology is enabling the work systems That have already been installed in 35% of our line and are generating very meaningful actionable data. And as part of our winning portfolio focus, we optimized production of higher margin SKUs, which drove 40 of the 2 basis points year over year gross margin uplift within our Americas business. We also continued To realize synergies from acquisitions, which are tracking slightly ahead of expectations through the Q2, The HRA distributor transitions are already providing meaningful cost savings and margin expansion. As you know, the 2023 unfavorable EPS impact of $0.16 to $0.18 from the distributor transitions It's not expected to repeat in 2024.

Speaker 2

All these initiatives contributed to another quarter of consistent year over year results The total Perrigo net sales growth of more than 6%, gross margin expansion of 220 basis points And 18% operating income growth, a 47% EPS growth. Importantly, we ended the quarter with a very solid cash position. Other notable highlights from quarter 2 include strong organic net sales growth of 7% in our international business, Where we continue to hold share in growing markets and categories. This growth was broad based, which included cough cold, added parasites, insect repellent and In the U. S, more consumers are choosing store brands as compared to national brands, Evidenced by store brand volume share growth of 70 basis points over the last 13 weeks.

Speaker 2

As expected, Perrigo's share of total store brand was lower over the same 13 weeks due to planned SKU prioritization actions During the quarter, which again enhanced gross margin. Surprisingly, last month, The FDA approved OPILE, the first ever daily oral contraceptive available OTC in the U. S. It was a momentous day for our organization and one that comes at a pivotal time in the women's health space. I'd like to once again congratulate the entire Women's Healthcare team who have worked for nearly a decade to achieve this milestone.

Speaker 2

This approval highlights Perrigo's strong innovation that I just mentioned and Opel will be an important part of the building blocks of our long term sustainable growth. This switch will define a new category within women's health and break down traditional barriers for the 64,000,000 women To make up the total addressable market in the U. S. Uptake has the potential to be broad across consumers who are not insured or new to the category Using less effective methods or choose to switch from prescription to the OTC product. I've worked on a number of prescription to OTC As they typically garner strong retailer support, drive net new growth and in the case of Opel, open up an entirely new category in the OTC space.

Speaker 2

Retailers are also excited about this upcoming product launch. As you may have seen from news reports, 2 leading drug chain stores have disclosed that they expect to offer Opel. We have made this decision to fund prelaunch investments for Oak Hill, coinciding with an expected retailer channel fill Late this year, we continue to expect Oakville on retailer shelves in early 2024. This is a meaningful opportunity for our U. S.

Speaker 2

OTC And we plan to invest judiciously and with intent to smartly maximize reach of the Opel brand. As with any branded launch, we do not expect the product to be accretive to earnings for the 1st 12 to 24 months. In addition to Opal, I also want to provide early thoughts on our infant formula business. We recently completed the Gateway facility Good start brand acquisition and that integration remains on track. In the Q2, this acquisition contributed $44,000,000 of net sales In our nutrition category, which was partly offset by $5,000,000 from a discontinued product line, a $5,000,000 of lower net sales Within the nutrition business, net sales of our legacy infant formula products were up $6,000,000 Or 6% despite lapping a strong comparison in the prior year due to a national brand supply issue.

Speaker 2

More on that in a moment. 2nd quarter gross margin in Nutrition expanded 7 30 basis points compared to the prior year and nearly 1200 basis points This is a solid business. As for the prior year national brand supply issue that I just mentioned, Perrigo stepped up to supply as much Formula to parents is possible by running our facilities 20 fourseven and prioritizing our highest volume SKUs to reduce production complexity, Therefore, achieving more than 115 percent infant formula output, a truly heroic effort by the team. Looking at the current landscape for infant formula, the market is normalizing as the impacted national brand has returned with many of its SKUs. Additionally, recent changes to FDA guidelines are impacting the entire industry, resulting in lower manufacturing volumes, higher production costs And higher risk of scrap.

Speaker 2

Reassuringly, there is more demand for our store brand formula than we can supply. We have not lost any distribution and we've used pricing actions to offset higher costs. We're now working to reintroduce SKUs that would deprioritize last year And to restock all customer shelves. But given the impact of the new regulations, this will take time. The healthy growth of our youngest consumer is our utmost priority, and our team is working relentlessly to ensure families have the nutritionally I'd like to conclude by reinforcing a few essential points to achieving Perrigo's full potential.

Speaker 2

Perrigo is well positioned in the self care industry and has a number of tools to differentiate against competition. I know how hard my colleagues have worked to make that happen. Our job now is to put these pieces together and to continuously innovate in everything we do to Including cash flow generation and deleveraging. Our 2025 growth algorithm shared in February Remains on track and I'm focused on plans to optimize and unlock our full potential and accelerate and sustain Top performance. As you may expect, I'm working with our global businesses to assess our market positioning and our long term plans.

Speaker 2

Work is already underway on winning initiatives. I look forward to sharpening my thinking as I continue getting to know the organization and team And then sharing more details in due course. With that, I'd like to thank you all. I will now turn it over to our CFO, Eduardo.

Speaker 3

Thank you, Patrick, and good morning, everyone. Before diving to the quarter, on behalf of our Entire operating committee, I would like to welcome Patrick to the Perrigo team. Since joining, he has brought a tremendous amount of energy and knowledge to our And we look forward to working with him as we continue to execute on our self care strategy. Now of course, it's music to my ears When I hear Patrick talk about our intense focus on cash. Starting with our GAAP to non GAAP summary, The company reported GAAP income of $9,000,000 for the 2nd quarter or GAAP earnings of $0.06 per diluted share.

Speaker 3

Adjusted net income was $87,000,000 and adjusted diluted earnings per share was $0.63 Per share versus $0.43 per share in the prior year quarter. Adjustments to the quarterly pre tax non GAAP P and L Include a net total of approximately $70,000,000 driven primarily by amortization expenses of $70,000,000 Restructuring charges of CAD 6,000,000 and the removal of CAD 10,000,000 of legacy royalty income received in the 2nd quarter. Full details can be found in the non GAAP reconciliation table attached to this morning's press release. From this Going forward, all dollar numbers, basis points and margin percentages will be on an adjusted basis unless stated otherwise. Total Perrigo reported net sales grew 6.4%.

Speaker 3

Organic growth was 80 basis points, Including an unfavorable 2.7 percentage points impact from proposal SKU prioritization actions to enhance margin. For CSTA, organic sales declined 2.7%, including an unfavorable 4.1 percentage points impact from the SKU prioritization I just mentioned. Light allergy season in the U. S. Also impacted organic growth by negative 1.8 percentage points.

Speaker 3

Within CSCI, organic growth Remain robust, up 7.1% compared to the prior year as our brands continue to resonate with consumers. Gross profit increased $52,000,000 or 13% driven by strategic pricing, acquisitions and favorable mix. These were partially offset by inflation, primarily in CSCI, lower manufacturing productivity in CSCA Nutrition Staring from the infant former regulations Patrick discussed and the HRA distribution transition sales returns. Operating income increased CAD21 1,000,000 or 18% driven by gross profit flow through, Partially offset by operating expenses from acquisitions. Before we discuss margins, a bit on the 2nd quarter effective tax rate, Which was 7.3% versus 23.9% last year.

Speaker 3

The difference was due primarily to the release of reserves And other tax attributes associated with the settlement of various tax matters, including a discrete benefit Of 0 point 0 $8 per share in the 2nd quarter. In total, these factors led to an impressive 46.5% EPS growth versus the prior year. Total Perrigo gross and operating margins expanded to 120 And 110 basis points year over year respectively. In CSCA, gross margin expanded to 160 basis points Driven by the same factors that drove gross profit in addition to the benefits from SKU prioritization. Operating margin expanded 80 basis points due to favorable gross margin flow through, partially offset by higher operating expenses Due to the addition of gateway and increased promotional investments.

Speaker 3

In CSCI, Gross margin expanded 30 basis points due to the same factors that drove gross profit, while operating margin increased 210 basis points driven by favorable operating leverage. Cash on hand At the end of the quarter was CAD555 1,000,000 reflecting an increase of CAD70 1,000,000 from Q2 last year. Operating cash flow for the quarter was CAD 53,000,000 and operating cash conversion of 61 percent to adjusted net income And returned $37,000,000 to shareholders through dividends. We continue to make steady progress in reducing our net leverage As we ended the quarter at 5.1 times net debt to adjusted EBITDA versus 5.5 times at the end of 2022. Turning now to guidance.

Speaker 3

We are firming our 2023 reported and organic net sales growth guidance and EPS range, Which is comprised of several factors, including unexpected adjusted tax rate for the second half of twenty twenty three Of approximately 19.5%, leading to a full year adjusted tax rate of approximately 17%, Including the 2nd quarter adjusted earnings per share discrete tax benefit of $0.08 per share. Investments in OPO pre launch activities, including building launch quantities and marketing and advertising plans to support a late 4th quarter retail channel fuel ahead of product getting to shelves in early 2024. The current dynamics In the infant formula industry that Patrick discussed and an assumed normal 2023 cough and cold season. In total, our guidance reflects the strength of our business and the balancing of opportunities and risks That we're currently managing. Given these assumptions and our typical earnings phasing, we anticipate second half earnings per share We'll be more heavily weighted towards the Q4, approximately 60% of our second half earnings.

Speaker 3

In closing, I would like to thank our colleagues around the world for their efforts. We continue to progress our strategic initiatives While meeting the needs of consumers around the world. With that, I will now turn the call back to Brad. Brad?

Speaker 1

Thank you, Eduardo. Vishnavi, can we now please open the line for questions?

Operator

Thank you. We will now begin the question and answer session. At this time, we will pause momentarily to assemble our roster. Our first question comes from Chris

Speaker 4

Maybe my first question is, you mentioned several areas of focus in the framework for sustained growth.

Speaker 3

Can you

Speaker 4

maybe just help us a little bit understand in terms of Your top priorities moving into the seat, which of these are kind of the biggest opportunities you see for Perrigo as we think about, Is this about some of the performance issues the company has, is it about portfolio? Is it about the focus? Is it consistency of manufacturing? Just maybe help us a little bit about how you're prioritizing those initiatives?

Speaker 2

Yes. Good morning, Chris. Thank you for the question. I've worked through in detail the strategic plan for the company. Job number 1 is we have to deliver those priorities.

Speaker 2

They're going to have the most impact on cost and cash and our OI growth. They include the supply chain reinvention, the integration and that's both HRA and the new production facility that we have, we bought from Nestle in Wisconsin. So call that landing the big strategic initiatives, all right? And those are foundational To the 2025 growth algorithm that we've committed and I see no reason to challenge that. 2nd part of focus for us is really just getting to operating a greater level of operating discipline.

Speaker 2

I'm starting to see that and that's particularly needed in the U. S. Business. So the second tranche of my focus is in primarily in the U. S.

Speaker 2

And that does involve really looking at our portfolio and where we need to double down, where we have the greatest right to win and it's the most attractive financially. That work is happening now. Then we need to look longer term and it's continuous work of sustainable growth. So So as we then look to the future, starting to look at the within our categories, which are the most attractive within our brands, In our country brand combinations, where do we see the greatest opportunities for growth and what is the investments and the capability that's needed to That block of work will probably start later on in the fall That will really guide where we focus in the future. So plan the initiatives, drive what I call the 1 Perrigo operating system and discipline, And then really make sure we're focused on what it takes for sustainable growth.

Speaker 4

Perfect. And just as part of that answer, it sounds like I guess my second question was just The 2025 targets that the company provided earlier this year, it sounds like you're comfortable with those ranges that were provided?

Speaker 2

I am comfortable. I've worked through them as you would hope and expect in detail. I think they're very well considered. I think we have the right action Plans and governance in place, but they have to be delivered. And I will stay on top of that governance personally To make sure each of them is on track and how we help the teams to stay on track.

Speaker 4

Great. And then my final question was just A little bit more color on how you're thinking about OPIL, in terms of both the investment needed to build that market and how large of an opportunity. So I guess specifically, I know you mentioned it's not going to be an earnings contributor in the 1st 12 to 24 months, but I think investors have been worried this actually could be a meaningful drag On results in that timeframe, can you just any color there would be appreciated. And then if you're willing to share a peak sales forecast for that product will also be

Speaker 2

Thank you, Chris. I'll let Eduardo talk more to the financials. We're deep in the commercialization process of that. We will start to ship later on this fall on shelves early 2024 And the commercial package for that is really what you would expect for any CPG brand launch. As I look at the plans, They're solid.

Speaker 2

They're solid. It's a complex sell to consumers given the nature of the category. And we're doing a lot of work on what is that awareness to trial conversion process, what investment and consumer touch points are required And how long that takes? So at this stage, I think until really that work is completed to a detail that I'm happy with, I wouldn't want to predict what the sales are, but I certainly will have a much better idea of the next earnings announcement. But for So the financials, Eduardo?

Speaker 3

Yes. So thanks, Patrick. Just to complement, Chris, what Patrick mentioned. So As you heard us saying, so in the second half, we're going to have an important investment To fund these activities and we're using the tax benefit that we realized in the Q2 to fund that. An important thing is we do not expect at least in the 1st 12 to 24 months for the Opio to be accretive as we View the brand nationwide and make sure this is going to be a successful launch for the long term.

Speaker 1

Thanks so much. Next question please.

Operator

Your next question comes from Susan Anderson with Canaccord. Please go ahead.

Speaker 5

Hi, good morning. Alec Legg on for Susan. First, welcome, Patrick, and congratulations on the new role. Thank you very much. You're welcome.

Speaker 5

Just a quick question on the U. S. Business. What are you seeing with the inventory levels at retail? Do you think you're back to more stabilized levels there?

Speaker 5

Or are there still categories that have some pockets of restocking opportunities left?

Speaker 3

Yes. Thank you for the question, Eduardo here. So as we look into the inventory levels at the retail now, we see them pretty normalized, Right. So after last year that we had a very strong cough and cold season that went up to Q2 We saw depletion of inventories this year. We saw in the Q1 a strong pickup, but a very normalized Season in the Q2, so we believe that this is giving time to have more normalization of inventories on the retail channel.

Speaker 3

And of course, we expect that for the 2023, 2024 cough and cold season in particular to be a normal season. So we do expect that there should be a pickup on Sales in the 3rd Q4 that were built in our guidance that we shared this morning.

Speaker 5

Perfect. And then just a follow-up on the units first pricing dynamic in the U. S. And internationally. It looks like pricing Added, I think, 4.8 points of sales growth in the quarter.

Speaker 5

Yes. Are you expecting more pricing to flow through the rest of the year? How are you thinking about Potential price taking the rest of the year and long term?

Speaker 3

Yes. So the first half, Mainly on the OTC, we had the pickup of the remaining pricing actions that we had last year and we continue to look into opportunities In the second half in the U. S, but very important as we mentioned in the Q1, Because of the disruptions on the infant formula business, we had to take stronger price actions and those were Communicated early July, and so we remain on track on our price projections for the second In the Nutrition business as well as in the International business, we continue to price To the value proposition of our brands and we're more than offsetting inflation that we continue to see impacting our COGS.

Speaker 5

Thank you. And then last question on the European consumer, looks like they've held up pretty strong And the consumption habits there have been trending pretty high, I guess. What else are you seeing over there? Is there any risk of trade down there? It seems like it's the opposite whereas in the U.

Speaker 5

S, we're not really seeing as much trade down to the private label, but it's the opposite and benefiting Perga, over in Europe.

Speaker 3

Yes. We continue to see a very strong pickup there. With our HRA brands as well, we're seeing a very good performance. And now starting in the second quarter, It becomes organic growth, but we saw also in several different categories, Coughing coat, parasites, insect repellent and skincare, a very strong update in the Q2 and we continue to see that And we expect that to continue for the second half of the year.

Speaker 1

Yes. And Alex, this is Brad. I'll just jump in on the U. S. Comment that you made.

Speaker 1

We are starting to see a little bit of that trade down impact. You saw it in the materials, the earnings materials from today that the volumes Within the U. S, store brand in particular are starting to gain some share. Of course, there's a little differential on the dollars as Some of the national brands may have taken more sizable dollar price increases, but the volume is starting to pick up in store brand, which I think Just an important factor to think about going forward.

Speaker 5

Yes. Very helpful. Thanks. I'll turn it back.

Speaker 1

Thank you. Next question please.

Operator

Thank you. Our next question comes from Daniel Bialysee with Head Guy. Please go ahead.

Speaker 6

Hi, thanks for the question. So wondering if you could go into a little more detail what the early learnings from the supply chain reinvention program are. It sounds like you've seen some gross margin benefits. Any reactions from customers about products that you're not going to make?

Speaker 3

Yes. So two key things That we're seeing is, as you saw in the Q2, we had about 40 basis points improvement in gross margin Slide to the SKU prioritization, that's really part of our winning portfolio pillar on the supply chain reinvention. So And again, remember, our first one thousand SKUs that we mentioned are going to focus, those were SKUs that we Did I have a major impact on overall on how we handle with the retailers? We're going to be moving soon to the next phase on how do we continue to simplify our portfolio and We continue to drive more value in our OTC category mainly. The other thing is important to highlight is On our Perrigo work systems, so Patrick mentioned about the number of lines that we're moving this new red zone equipment.

Speaker 3

And So we're seeing a very important improvement in efficiency on our lines. So this is helping not only to Expand capacity for certain categories that are so needed, like in cough and cold, but also this will help us manage Better our inventories and our working capital towards the end of this year years to come.

Speaker 6

Okay. Thank you. And then can I also ask what you're seeing in the M and A in the consumer healthcare space? It seems like it's picking up and Maybe if you can remind us where deleveraging falls in as a focus for the balance sheet?

Speaker 3

Yes. So Yes. We're seeing several activities going on in the marketplace with different companies trying To streamline their portfolios, as in terms of our guidance and our commitment, right, so we expect to Be around 3 times EBITDA in terms of net leverage by 2025. So our 3 main commitments in terms of how How we're going to use our cash that's going to be generated over the next 3 years, it's making sure we reinvest in our business To make sure our supply chain reinvention is fully successful, also look into how we optimize our Nutrition production capabilities as well as returning value to our shareholders And reducing our debt, we have a tranche of $700,000,000 debt that matures at the end of next year.

Speaker 1

And then just this is Brad again. Just to reinforce Eduardo's comment here, we've basically taken out through EBITDA growth over the 6 months, almost a half a turn, has come out. So the leverage is just sitting a little bit north of 5 year from 5.5 just about 6 months ago.

Operator

This concludes our question and answer session. I would like to turn the conference back over to Bradley Joseph for any closing remarks.

Speaker 1

Well, great. Thanks everybody for joining the call. We look forward to speaking with you soon. Thanks for your interest in Perrigo.

Operator

The conference has now concluded. Thank you for attending today's presentation. You may all now disconnect.

Powered by Quartr